- Home
- HROW vs RQI Comparison
HROW vs RQI Comparison
Compare HROW & RQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- RQI
- Stock Information
- Founded
- HROW 1998
- RQI 2002
- Country
- HROW United States
- RQI United States
- Employees
- HROW N/A
- RQI N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- RQI Trusts Except Educational Religious and Charitable
- Sector
- HROW Health Care
- RQI Finance
- Exchange
- HROW Nasdaq
- RQI Nasdaq
- Market Cap
- HROW 1.4B
- RQI 1.6B
- IPO Year
- HROW N/A
- RQI N/A
- Fundamental
- Price
- HROW $33.71
- RQI $12.01
- Analyst Decision
- HROW Strong Buy
- RQI
- Analyst Count
- HROW 7
- RQI 0
- Target Price
- HROW $68.50
- RQI N/A
- AVG Volume (30 Days)
- HROW 558.8K
- RQI 432.6K
- Earning Date
- HROW 11-10-2025
- RQI 01-01-0001
- Dividend Yield
- HROW N/A
- RQI 8.20%
- EPS Growth
- HROW N/A
- RQI N/A
- EPS
- HROW N/A
- RQI N/A
- Revenue
- HROW $227,661,000.00
- RQI N/A
- Revenue This Year
- HROW $43.92
- RQI N/A
- Revenue Next Year
- HROW $41.22
- RQI N/A
- P/E Ratio
- HROW N/A
- RQI N/A
- Revenue Growth
- HROW 47.69
- RQI N/A
- 52 Week Low
- HROW $20.85
- RQI $9.17
- 52 Week High
- HROW $54.19
- RQI $12.64
- Technical
- Relative Strength Index (RSI)
- HROW 31.53
- RQI 39.25
- Support Level
- HROW $36.20
- RQI $11.87
- Resistance Level
- HROW $38.52
- RQI $12.04
- Average True Range (ATR)
- HROW 1.65
- RQI 0.16
- MACD
- HROW -0.43
- RQI -0.03
- Stochastic Oscillator
- HROW 10.74
- RQI 18.75
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.